Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: Implications for future HPV immunization

Sexually Transmitted Diseases

Volumn 33, Issue 4, 2006, Pages 259-264

  Bollen, Liesbeth J M ^a   Chuachoowong, Rutt ^a   Kilmarx, Peter H ^a,b   Mock, Philip A ^a   Culnane, Mary ^a,b   Skunodom, Natapakwa ^a   Chaowanachan, Thanyanan ^a   Jetswang, Bongkoch ^a   Neeyapun, Kanchana ^a   Asavapiriyanont, Suvanna ^c   Roongpisuthipong, Anuvat ^d   Wright, Thomas C ^e   Tappero, Jordan W ^a,b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c RAJAVITHI HOSPITAL   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYBRIDIZATION; IMMUNIZATION; INFECTION RISK; MAJOR CLINICAL STUDY; MOTHER; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; PROPHYLAXIS; THAILAND; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; THAILAND; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL VACCINES;

EID: 33645941816     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000187208.94655.34     Document Type: Article

References (37)

1. Parkin D, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841.
2. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993; 41:1-19.
3. Maiman M, Frucher R, Guy L, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76-80.
4. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37:1188-1201.
5. Chariyalertsak S, Sirisanthana T, Saengwonloey O, et al. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. Clin Infect Dis 2001; 32:955-962.
6. Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol 1999; 189:12-19.
7. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 6:271-278.
8. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 8:469-475.
9. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-789.
10. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353:773-780.
11. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for WHO staging system for HIV infection disease. Wkly Epidemiol Rec 1990; 65:221-228.
12. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 2000; 181:99-106.
13. National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. DAIDS Virology Manual for HIV Laboratories. Washington, DC: US Department of Health and Human Services; 1997. Publication NIH-97-3828.
14. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-361.
15. Kornegay JR, Roger M, Davies PO, et al. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and Interlaboratory agreement. J Clin Microbiol 2003; 41:1080-1086.
16. Gravitt P, Peyton CL, Apple RJ, et al. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36:3020-3027.
17. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-2119.
18. Ellerbrock TV, Chiasson M, Bush T, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2001; 283:1031-1037.
19. Cohn J, Gagnon S, Spence M, et al. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Am J Obstet Gynecol 2001; 3:322-330.
20. Clifford GM, Smith JS, Plummer M, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89:101-105.
21. Manos M, Waldman J, Zhang T, et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis 1994; 170:1096-1099.
22. Levi JE, Kleter B, Quint WGV, et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 2002; 40:3341-3345.
23. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-236.
24. Xu F, Kilmarx PH, Supawitkul S, et al. HIV-1 seroprevalence, risk factors, and preventive behaviors among women in Northern Thailand. JAIDS 2000; 25:353-359.
25. Lefevre J, Hankins C, Pourreaux K, et al. Prevalence of selective inhibition of HPV-16 DNA amplification in cervicovaginal lavages. J Med Virol 2004; 72:132-137.
26. Chan PKS, Chang AR, Tam WH, et al. Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and non-pregnant controls. J Med Virol 2002; 67:583-588.
27. Ahdieh L, Klein R, Burk R, et al. Prevalence, incidence and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-690.
28. Rugpao S, Nagachinta T, Wanapirak C, et al. Gynaecological conditions associated with HIV infection in women who are partners of HIV-positive Thai blood donors. Int J STD AIDS 1998; 9:677-682.
29. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187:1246-1256.
30. Sirivongrangson P, Bollen LJM, Virapat P, et al. Should women with HIV infection be screened for sexually transmitted infections? initial findings of a demonstration project in Bangkok, Thailand. XV International AIDS Conference, 11-16 July 2004, Bangkok, Thailand [abstract ThPeC7390].
31. Thomas D, Ray NB, Kuypers J, et al. Human papillomaviruses and cervical cancer in Bangkok: the role of husbands and commercial sex workers. Am J Epidemiol 2001; 153:740-748.
32. Burk R, Ho G, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174:679-689.
33. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada: survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000; 163:503-508.
34. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus types 1 and 2 infections. J Infect Dis 2003; 188:555-563.
35. Spinillo A, Debiaggi M, Zara F, et al. Human immunodeficiency virus type 1-related nucleic acids and papillomavirus DNA in cervicovaginal secretions of immunodeficiency virus-infected women. Obstet Gynecol 1997; 6:999-1004.
36. National Access to Antiretroviral Program for People with HIV/AIDS (NAPHA) in Thailand. Available at: http://www.aidsthai.org/aidsenglish/nation_care.html. Accessed November 14, 2005.
37. Amornwichet P, Teeraratkul A, Simonds RJ, et al. Preventing mother-to-child HIV transmission: the first year of Thailand's national program. JAMA 2002; 288:245-248.